Fig. 2From: Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinomaA Kaplan–Meier curves of cumulative PFS in recurrent HCC patients treated with TACE-camrelizumab or TACE-alone. HCC = hepatocellular carcinoma, PFS = progression-free survival. B Kaplan–Meier curves of cumulative PFS in recurrent HCC patients treated with TACE-camrelizumab or TACE-alone at the stage of BCLC-C. HCC = hepatocellular carcinoma, PFS = progression-free survival. BCLC = Barcelona Clinic Liver CancerBack to article page